

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **LifeTech Scientific Corporation**

**先健科技公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock code: 1302)**

### **VOLUNTARY ANNOUNCEMENT**

#### **Admission of the Lantval™ Aortic Valve Replacement System into Special Examination and Approval Procedure for Innovative Medical Devices**

This announcement is made by LifeTech Scientific Corporation (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis.

The board (the “**Board**”) of directors (“**Directors**”) of the Company is pleased to announce that on 9 September 2026, the Company obtained formal written notice from the National Medical Products Administration (“**NMPA**”) confirming that the Lantval™ Aortic Valve Replacement System (the “**Product**”), jointly developed by the Company’s subsidiary Shenzhen Lifevalve Medical Technology Co., Ltd. (“**Lifevalve Medical**”) and Fuwai Hospital, the Chinese Academy of Medical Sciences of the National Center for Cardiovascular Diseases, has been admitted into the NMPA Special Examination and Approval Procedure for Innovative Medical Devices (the “**Procedure**”). The Product is indicated for the surgical treatment of patients with aortic stenosis or aortic stenosis combined with regurgitation. It is the world’s first aortic valve replacement product featuring a fully pre-mounted, dry-valve, sutureless design, and the 18th product of the Company having obtained admission to the Procedure.

Aortic stenosis (AS) is one of the most prevalent valvular heart diseases. With the accelerating aging of the population in China, the number of patients with aortic valve diseases continues to rise. In particular, patients with severe aortic stenosis, if not treated promptly and effectively, often face poor prognosis and lower survival rates.

The Product combines the advantages of conventional surgical aortic valve replacement (SAVR) — including the removal of native calcified leaflets, reliable hemodynamic performance, and long-term durability — with the self-expanding, sutureless anchoring design mechanism of transcatheter aortic valve replacement (TAVR). For tissue processing, the project team has applied its self-developed innovative dry-pericardium tissue technology, which is intended to improve the storage and handling of bioprosthetic valves and further enhance long-term valve durability. The fully pre-mounted, ready-to-use design enables rapid implantation through minimally invasive small-incision approaches, reducing suturing maneuvers, significantly shortening operative time, and lowering procedural complexity. The Product thereby offers a novel solution for the surgical treatment of aortic valve diseases that balances minimally invasive attributes with superior performance.

The Product completed its first-in-man (FIM) clinical trial in 2025. Study data demonstrated that the implantation time was significantly shorter than that of conventional surgical valve replacement. All enrolled patients completed the primary endpoint follow-up and showed satisfactory postoperative recovery and quality of life. The FIM study results preliminarily validated the engineering and clinical feasibility of the first-of-its-kind integrated surgical valve replacement product featuring a “dry-valve + fully pre-mounted + sutureless” design, highlighting its clinical value in simplifying surgical procedures, shortening valve implantation time, reducing the risk of paravalvular leak, improving hemodynamics, and enhancing valve durability.

The Group possesses independent intellectual property rights to the Product. The pre-market registration clinical study for the Product is about to be initiated. With the steady progress of subsequent clinical trials, there will be more high-quality evidence-based medicine (EBM) evidence to further confirm the safety and effectiveness of the Product.

The Board believes that the admission of the Product into the Procedure will facilitate its research, development and clinical translation, and accelerate its commercialization process in China. Currently, there is no domestically manufactured sutureless aortic valve product approved for marketing in China. The Product is expected to fill the gap in the domestic market and offer a better therapeutic option for the vast population of patients with aortic stenosis.

By order of the Board  
**LifeTech Scientific Corporation**  
**XIE Yuehui**

*Executive Director, Chairman and Chief Executive Officer*

Hong Kong, 10 September 2026

*As at the date of this announcement, the Board comprises Mr. XIE Yuehui, Ms. WU Liping and Mr. FANG Yu being executive Directors; and Mr. ZHOU Luming, Ms. CHEN Dongxia and Mr. JIANG Feng being independent non-executive Directors.*